[1] American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders[M]. DSM-Ⅳ，1994.
[2] SUN D F， YI M J， LI Y L. Survey of attention deficit hyperactivity disorder among 6-16 years old children in BinZhou City， Shandong[J]. Chin Ment Health J(中国心理卫生杂志)， 2009， 23(11):806-809.
[3] COMIER E.Attention deficit／hyperactivity disorder:a review and update [J]. J Pediatr Nurs， 2008， 3（5）:345-357.
[4] ELIA J．Drug treatment for hyperactive children：therapeutic guidelines [J]. Drugs，1993， 46:863-871.
[5] YAN X P， ZHENG Y， CUI Y H. Attention-Deficit／Hyperactivity Disorder and juvenile delinquency [J]. Chin Ment Health J(中国心理卫生杂志)， 2010， 24(8):609-612.
[6] CARLSON C L， TAMM L， GAUB M.Gender differences in children with ADHD， ODD， and co-occurring ADHD/ODD identified in a school population [J]. J Am Acad Child Adolesc Psychiatry， 1997， 36(12):1706-1714.
[7] XU T， ZHOU Y， WEI H W， et al. Comparison of atomoxetine and methylphenidate for treating children with attention deficit hyperactivity disorder[J]. Chin J Pract Pediatr(中国实用儿科杂志)， 2008， 23(7):499-501.
[8] Caballero.Adding 8 weeks of behavioural therapy to atomoxetine does not improve classroom behaviour in children with ADHD[J]. Evid Based Ment Health， 2011， 14(3):83.
[9] Garnock-Jones KP， Keating GM.Atomoxetine:a review of its use in attention-deficit hyperactivity disorder in children and adolescents[J]. Paediatr Drugs， 2009， 11(3):203-226.
[10] Suzanne McCarthy， Noel Cransweick， Laura Potts， et al. Mortality associated with attention-deficit hyperactivity disorder(ADHD) drug treatment[J]. Drug Saf， 2009， 32(11):1089-1096.
[11] GRAHAM J， BANASCHEWSKI T， BUITELAAR J， et al European guidelines on managing adverse effects of medication for ADHD[J]. Eur child adolesc psychiatry， 2011， 20:17-37.